GlassScriptPhysician profile
David A Brosman
NPI 1023113008
$4,009.00
in general payments reported to CMS, 2019-2025
27 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $510 · 2021: $537 · 2022: $584 · 2023: $555 · 2024: $183 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,500.43 | 2019-2025 | Eterna, Proclaim, Octrode |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $546.70 | 2019-2025 | Relistor |
| Flowonix Medical Incorporated | $361.69 | 2019 | |
| Medtronic, INC. | $320.37 | 2021-2024 | Synchromedii, Intellis Adaptivestim |
| Nevro Corp. | $295.96 | 2019-2021 | |
| Tersera Therapeutics LLC | $206.26 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $182.42 | 2019-2022 | |
| Forte Bio-Pharma LLC | $136.59 | 2021-2022 | |
| Medtronic USA, INC. | $105.53 | 2019-2020 | |
| Pfizer INC. | $39.67 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $28.06 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.73 | 2025 | |
| Bioventus LLC | $25.50 | 2023 | Durolane |
| Metacel Pharmaceuticals LLC | $21.42 | 2023 | Ozobax |
| Protega Pharmaceutials INC | $21.41 | 2023 | Roxybond |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.55 | 2019 | |
| Boston Scientific Corporation | $18.38 | 2019 | |
| Baudax Bio INC. | $17.78 | 2020 | |
| Grt US Holding, INC. | $17.44 | 2021 | |
| Convatec INC. | $17.38 | 2024 | |
| Sentynl Therapeutics, INC. | $16.88 | 2019 | |
| Abbvie INC. | $16.51 | 2021 | |
| Shionogi INC | $14.02 | 2019 | |
| Biodelivery Sciences International, INC. | $13.60 | 2020 | |
| Pacira Therapeutics, INC. | $13.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.75 | 2022 | |
| Redhill Biopharma INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.